Early Xeloda does not help in breast cancer- study

	Tweet

Older breast cancer patients who got Roche AG’s drug Xeloda all by itself were almost twice as likely to relapse and die than women who got standard chemotherapy, U.S. researchers reported on Wednesday.

Although the drug works well against breast cancer that has spread, it did not prevent spread in women with early-stage breast cancer, the researchers reported in Thursday’s New England Journal of Medicine.

The drug, whose generic name is capecitabine, can be taken as a pill and would be more convenient and less toxic than infusions of chemotherapy. But the trial showed it was not nearly as effective.

"Patients who were randomly assigned to capecitabine were twice as likely to have a relapse and almost twice as likely to die as patients who were randomly assigned to standard chemotherapy,” Dr. Hyman Muss of the University of Vermont and colleagues wrote.

“The study was designed to show it was just as good” as standard treatment for early-stage breast cancer, Muss said in a telephone interview. “It didn’t work out.”

Xeloda did particularly poorly in hormone-receptor-negative tumors, which also cannot be treated with pills such as tamoxifen.

The study is one of the few to look at the effectiveness of breast cancer chemotherapy in older women. Most tests look at younger patients, even though the majority of the 40,000 breast cancer deaths in the U.S. occur in women age 65 and older.

Three years after beginning treatment, 91 percent of the 326 women getting the more aggressive—and more toxic - conventional chemotherapy were alive compared to 86 percent of the 307 who were taking Xeloda tablets.

In the Xeloda group, nearly half the deaths were caused by the breast cancer itself. In the conventional-therapy group, heart disease or other types of cancer were the most common causes.

By Gene Emery
BOSTON (Reuters Life!)

RELATED STORIES:
Taxol-type Drugs Give Slight Boost to Survival Rates in Early Breast Cancer   Adapting Space-Industry Technology to Treat Breast Cancer   Sisters of women with breast cancer joining study   Targeted Immunotherapy: Metastatic Breast, Pancreatic Cancers   Computer Based Model Helps Radiologists Diagnose Breast Cancer   Early Stage, HER2 Positive Breast Cancer Patients at Increased Risk of Recurrence   “Glycemic load” of diet tied to breast cancer risk   GW researchers reveal digital transcriptome of breast cancer   Cell of Origin Identified for Common Type of Breast Cancer   New Test Discovered to Better Predict Breast Cancer Outcomes   Full Field Digital Mammography: A New Breast Cancer Screening Tool   Low-dose radiation may raise breast cancer risk   Test can reduce recurrence of breast cancer   Breast cancer regimen linked to cognitive decline   Breast cancer tumor growth estimated through mammography screening data   Obesity linked with poorer breast cancer outcomes   Integrating genetic information with breast cancer risk factors may help refine prognosis   Plant-rich diets tied to lower breast cancer risk   New Tool to Diagnose and Treat Breast Cancer   Few women take tamoxifen to prevent breast cancer   Iressa Shows Promise For Treatment of Metastatic Breast Cancer When Combined With Hormonal Therapy   Breast cancer risk higher in young smokers

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]